REGNRegeneron PharmaceuticalsFinished
Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer
Non-small Cell Lung Cancer
5Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +4.8
5 insiders sold shares within a month
Since Nov 4, 2026 · was worth 5, fading over time
Worry score5
Score over time
- Stage
- Phase 3
- Patients
- 789 (final count)
- Started
- Mar 6, 2018
- Main results expected
- Feb 27, 2025
- Fully finished
- Feb 27, 2025
- Results posted
- Apr 29, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Overall Survival (OS)
Measured over: Up to a maximum of 82.2 months
Part 2: OS
Measured over: Up to a maximum of 68.4 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03409614 · record last updated 2026-05-18 · checked 2026-11-09 15:47 UTC